Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

5.09

Today's Change

+0.23 (4.73%)

Day's Change

4.87 - 5.11

Trading Volume

911,678

Overview

Market Cap

1 Billion

Shares Outstanding

311 Million

Avg Volume

1,251,001

Avg Price (50 Days)

4.13

Avg Price (200 Days)

2.49

PE Ratio

-42.42

EPS

-0.12

Earnings Announcement

21-Aug-2024

Previous Close

4.86

Open

4.95

Day's Range

4.87 - 5.11

Year Range

0.695 - 5.67

Trading Volume

911,678

Price Change Highlight

1 Day Change

4.73%

5 Day Change

5.17%

1 Month Change

17.01%

3 Month Change

79.23%

6 Month Change

169.31%

Ytd Change

142.38%

1 Year Change

656.42%

3 Year Change

239.33%

5 Year Change

239.33%

10 Year Change

239.33%

Max Change

239.33%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment